…practical guide…
Existing commercial interests in the medical psychedelics sphere may unfortunately be ambivalent about, or even actively obstruct wider reform efforts where they perceive it as undermining progress towards medical or therapeutic commercialisation… [therefore] exploring options for non-commercial market models can also be an important component of this strategy. This should certainly include allowing home cultivation, foraging and not-for-profit sharing of plant-based psychedelics, and membership based not-for-profit associations — which can go some way to limiting the scale of commercial markets by providing alternative forms of access
Without adequate protection, this can lead to corporate/regulatory capture, the process by which corporate resources (legal, financial, advocacy and PR) are deployed to shape market architecture and policy and law-making processes in favour of corporate profits, over embedding social justice, equity and human rights into policy design the interests of the wider public. There is already a vast amount of speculative investor capital flowing into the emerging medical/therapeutic psychedelics market. It is therefore imperative that any regulatory framework for psychedelics is designed to prevent the emergence of monopolies and mitigate the attendant risks of corporate/regulatory capture. Crucially, such efforts must be hardwired into the regulatory framework from the outset. As global alcohol and tobacco markets have shown, allowing problematic market dynamics dominated by powerful transnational corporations to become established and embedded makes regulatory reforms in the future much more difficult, although not impossible.
Original Article (Transform):
How to regulate psychedelics: A practical guide
Artwork Fair Use: pd4u
Recent Comments